echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Gan Lai announced the approval of the U.S. clinical trial application for the first dual target fixed-dose compound preparation of its kind ASC43F for the treatment of non-alcoholic steatohepatitis

    Gan Lai announced the approval of the U.S. clinical trial application for the first dual target fixed-dose compound preparation of its kind ASC43F for the treatment of non-alcoholic steatohepatitis

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanghai, November 1, 2021/PRNewswire/ - Golly Pharmaceutical Co.


    ASC43F is a fixed-dose single-tablet compound preparation consisting of ASC41 and ASC42, taken once a day


    The approval of the US IND is based on the efficacy data of the combination of ASC41 and ASC42 in the rat NASH model.


    Dr.


    Dr.


    About songli

    Gale is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.


    1.


    Source: Golly Pharmaceutical Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.